A phase i study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours

British Journal of Cancer

Volumn 103, Issue 1, 2010, Pages 12-17

  Lassen, U ^a   Molife, L R ^b   Sorensen, M ^a   Engelholm, S A ^a   Vidal, L ^b   Sinha, R ^b   Penson, R T ^c   Buhl Jensen, P ^d   Crowley, E ^d   Tjornelund, J ^d   Knoblauch, P ^d   De Bono, J S ^b  

^a Rigshospitalet   (Denmark)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d TopoTaget A/S   (Denmark)

Author keywords

BelCaP; belinostat; carboplatin; HDAC; paclitaxel

Indexed keywords

BELINOSTAT; CA 125 ANTIGEN; CARBOPLATIN; PACLITAXEL; ANTINEOPLASTIC AGENT; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID;

ADULT; AGED; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; BILE DUCT CARCINOMA; BLADDER CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CHONDROSARCOMA; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG MEGADOSE; DRUG SAFETY; FATIGUE; FEMALE; HOT FLUSH; HUMAN; LEUKOPENIA; LIVER CELL CARCINOMA; MALE; MELANOMA; MESOTHELIOMA; MIXED MULLERIAN TUMOR; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; OPEN STUDY; OPTIMAL DRUG DOSE; OVARY CARCINOMA; PANCREAS CANCER; PANCREAS CARCINOMA; PERIPHERAL SENSORY NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECTUM CANCER; RECTUM CARCINOMA; SENSORY NEUROPATHY; SOFT TISSUE SARCOMA; SOLID TUMOR; STOMACH CARCINOMA; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; MIDDLE AGED; NEOPLASM;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; FEMALE; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; MALE; MIDDLE AGED; NEOPLASMS; PACLITAXEL;

EID: 77954167626     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605726     Document Type: Article

References (22)

1. Bhalla KN, Kumar GN, Walle UK, Ibrado AM, Javed T, Stuart RK, Reed C, Arbuck SG, Walle T (1999) Phase I and pharmacologic study of a 3-h infusion of paclitaxel followed by cisplatinum and 5-fluorouracil in patients with advanced solid tumors. Clin Cancer Res 5: 1723-1730
2. Bolden JE, Peart MJ, Johnstone RW (2006b) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5: 769-784
3. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7: 1748-1756
4. Gimsing P, Hansen M, Knudsen LM, Knoblauch P, Christensen IJ, Ooi CE, Buhl-Jensen P (2008) A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia. Eur J Haematol 81: 170-176
5. Goffin JR, Anderson IC, Supko JG, Eder Jr JP, Shapiro GI, Lynch TJ, Shipp M, Johnson BE, Skarin AT (2005) Phase I trial of the matrix metalloproteinase inhibitor marimastat combined with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. Clin Cancer Res 11: 3417-3424
6. Grunstein M (1997) Histone acetylation in chromatin structure and transcription. Nature 389: 349-352
7. Jelliffe RW (1973) Letter: creatinine clearance: bedside estimate. Ann Intern Med 79: 604-605
8. Khan N, Jeffers M, Kumar S, Hackett C, Boldog F, Khramtsov N, Qian X, Mills E, Berghs SC, Carey N, Finn PW, Collins LS, Tumber A, Ritchie JW, Jensen PB, Lichenstein HS, Sehested M (2008) Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J 409: 581-589
9. Marchion DC, Bicaku E, Daud AI, Richon V, Sullivan DM, Munster PN (2004) Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid. J Cell Biochem 92: 223-237
10. Marchion DC, Bicaku E, Daud AI, Sullivan DM, Munster PN (2005) In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates. Mol Cancer Ther 4: 1993-2000
11. Marks P, Rifkind RA, Richon VM (2001) Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1: 194-202
12. Marks PA, Dokmanovic M (2005) Histone deacetylase inhibitors: discovery and development as anticancer agents. Expert Opin Investig Drugs 14: 1497-1511
13. Munster P, Marchion D, Bicaku E, Schmitt M, Lee JH, DeConti R, Simon G, Fishman M, Minton S, Garrett C, Chiappori A, Lush R, Sullivan D, Daud A (2007) Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. J Clin Oncol 25: 1979-1985
14. Munster PN, Marchion D, Thomas S, Egorin M, Minton S, Springett G, Lee JH, Simon G, Chiappori A, Sullivan D, Daud A (2009) Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker. Br J Cancer 101: 1044-1050
15. Oguri S, Sakakibara T, Mase H, Shimizu T, Ishikawa K, Kimura K, Smyth RD (1988) Clinical pharmacokinetics of carboplatin. J Clin Pharmacol 28: 208-215
16. Piekarz RL, Frye AR, Wright JJ, Steinberg SM, Liewehr DJ, Rosing DR, Sachdev V, Fojo T, Bates SE (2006) Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Clin Cancer Res 12: 3762-3773 (Pubitemid 44000258)
17. Plumb JA, Finn PW, Williams RJ, Bandara MJ, Romero MR, Watkins CJ, La Thangue NB, Brown R (2003) Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol Cancer Ther 2: 721-728
18. Qian X, LaRochelle WJ, Ara G, Wu F, Petersen KD, Thougaard A, Sehested M, Lichenstein HS, Jeffers M (2006) Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies. Mol Cancer Ther 5: 2086-2095
19. Ramalingam SS, Parise RA, Ramanathan RK, Lagattuta TF, Musguire LA, Stoller RG, Potter DM, Argiris AE, Zwiebel JA, Egorin MJ, Belani CP (2007a) Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies. Clin Cancer Res 13: 3605-3610
20. Schemies J, Sippl W, Jung M (2009) Histone deacetylase inhibitors that target tubulin. Cancer Lett 280: 222-232
21. Steele NL, Plumb JA, Vidal L, Tjornelund J, Knoblauch P, Rasmussen A, Ooi CE, Buhl-Jensen P, Brown R, Evans TR, DeBono JS (2008) A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin Cancer Res 14: 804-810
22. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92: 205-216 (Pubitemid 30099779)